LEHNES PHARMACOLOGY FOR NURSING CARE 10TH EDITION BURCHUM TEST BANK Q&
Chapter 03: Drug Regulation, Development, Names, and Information
Test Bank
MULTIPLE CHOICE
1. A nurse educator is conducting a continuing education class on pharmacology. To evaluate the
learning of the nurses in the class, the nurse educator asks, “Which drug name gives information
about the drug’s pharmacologic classification?” Which is the correct response?
a Amoxicillin
.
b Tylenol
.
c Cipro
.
d Motrin
.
ANS: A
Amoxicillin is the generic name, and the suffix “-cillin” indicates that it belongs to the penicillin
class of antibiotics. Tylenol, Cipro, and Motrin are all trade names without segments that indi-
cate their pharmacologic class.
PTS: 1 DIF: Cognitive Level: Comprehension REF: p. 18
TOP: Nursing Process: Diagnosis NURSINGTB.COM
MSC: NCLEX Client Needs Category: Physiologic Integrity: Pharmacologic and Parenteral Therapies
2. The FDA Amendments Act (FDAAA) was passed in 2007 to address which aspect of drug
safety?
a Allowing pharmaceutical companies to identify off-label uses of medications approved for other uses
.
b Evaluating drug safety information that emerges after a drug has been approved and is in use
.
c Expediting the approval process of the U.S. Food and Drug Administration (FDA) so that needed drugs ca
. market more quickly
d Requiring manufacturers to notify patients before removing a drug from the market
.
ANS: B
The FDAAA was passed to enable the Food and Drug Administration to continue oversight of a
drug after granting it approval so that changes in labeling could be made as necessary and post-
marketing risks could be tracked and identified. A provision of the FDA Modernization Act
(FDAMA), passed in 1997, allows drug companies to promote their products for off-label uses as
long as they promise to conduct studies to support their claims. Regulations to permit accelerated
approval of drugs for life-threatening diseases were adopted in 1992 by the FDA. The require-
ment that drug companies notify patients 6 months before removing a drug from the market is a
provision of the FDAMA.
PTS: 1 DIF: Cognitive Level: Comprehension REF: pp. 14-15
This study source was downloaded by 100000832361371 from CourseHero.com on 04-13-2022 07:34:28 GMT -05:00
https://www.coursehero.com/file/89019307/c3pdf/ NURSINGTB.COM
Chapter 03: Drug Regulation, Development, Names, and Information
Test Bank
MULTIPLE CHOICE
1. A nurse educator is conducting a continuing education class on pharmacology. To evaluate the
learning of the nurses in the class, the nurse educator asks, “Which drug name gives information
about the drug’s pharmacologic classification?” Which is the correct response?
a Amoxicillin
.
b Tylenol
.
c Cipro
.
d Motrin
.
ANS: A
Amoxicillin is the generic name, and the suffix “-cillin” indicates that it belongs to the penicillin
class of antibiotics. Tylenol, Cipro, and Motrin are all trade names without segments that indi-
cate their pharmacologic class.
PTS: 1 DIF: Cognitive Level: Comprehension REF: p. 18
TOP: Nursing Process: Diagnosis NURSINGTB.COM
MSC: NCLEX Client Needs Category: Physiologic Integrity: Pharmacologic and Parenteral Therapies
2. The FDA Amendments Act (FDAAA) was passed in 2007 to address which aspect of drug
safety?
a Allowing pharmaceutical companies to identify off-label uses of medications approved for other uses
.
b Evaluating drug safety information that emerges after a drug has been approved and is in use
.
c Expediting the approval process of the U.S. Food and Drug Administration (FDA) so that needed drugs ca
. market more quickly
d Requiring manufacturers to notify patients before removing a drug from the market
.
ANS: B
The FDAAA was passed to enable the Food and Drug Administration to continue oversight of a
drug after granting it approval so that changes in labeling could be made as necessary and post-
marketing risks could be tracked and identified. A provision of the FDA Modernization Act
(FDAMA), passed in 1997, allows drug companies to promote their products for off-label uses as
long as they promise to conduct studies to support their claims. Regulations to permit accelerated
approval of drugs for life-threatening diseases were adopted in 1992 by the FDA. The require-
ment that drug companies notify patients 6 months before removing a drug from the market is a
provision of the FDAMA.
PTS: 1 DIF: Cognitive Level: Comprehension REF: pp. 14-15
This study source was downloaded by 100000832361371 from CourseHero.com on 04-13-2022 07:34:28 GMT -05:00
https://www.coursehero.com/file/89019307/c3pdf/ NURSINGTB.COM
